Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;38(6):1769-1800.
doi: 10.1007/s11011-023-01225-3. Epub 2023 Jun 19.

Crosstalk between Alzheimer's disease and diabetes: a focus on anti-diabetic drugs

Golnaz Goodarzi #  1   2   3 , Sadra Samavarchi Tehrani #  1   2 , Saeed Ebrahimi Fana  1   2 , Hemen Moradi-Sardareh  4 , Ghodratollah Panahi  1 , Mahmood Maniati  5 , Reza Meshkani  6
Affiliations
Review

Crosstalk between Alzheimer's disease and diabetes: a focus on anti-diabetic drugs

Golnaz Goodarzi et al. Metab Brain Dis. 2023 Aug.

Abstract

Alzheimer's disease (AD) and Type 2 diabetes mellitus (T2DM) are two of the most common age-related diseases. There is accumulating evidence of an overlap in the pathophysiological mechanisms of these two diseases. Studies have demonstrated insulin pathway alternation may interact with amyloid-β protein deposition and tau protein phosphorylation, two essential factors in AD. So attention to the use of anti-diabetic drugs in AD treatment has increased in recent years. In vitro, in vivo, and clinical studies have evaluated possible neuroprotective effects of anti-diabetic different medicines in AD, with some promising results. Here we review the evidence on the therapeutic potential of insulin, metformin, Glucagon-like peptide-1 receptor agonist (GLP1R), thiazolidinediones (TZDs), Dipeptidyl Peptidase IV (DPP IV) Inhibitors, Sulfonylureas, Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors, Alpha-glucosidase inhibitors, and Amylin analog against AD. Given that many questions remain unanswered, further studies are required to confirm the positive effects of anti-diabetic drugs in AD treatment. So to date, no particular anti-diabetic drugs can be recommended to treat AD.

Keywords: Alzheimer's disease (AD); Amyloid-β protein; Anti-diabetic drugs; Insulin resistance; Tau protein; Type 2 diabetes mellitus (T2DM).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aali E, Esmaeili MH, Mahmodi SS, Solimani P (2020) Effects of chronic administration of pioglitazone on learning and memory in rat model of streptozotocin-induced Alzheimer’s disease. J Inflamm Dis 24(4):294–307
    1. Abdel-latif RG et al (2020) Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway. Arch Pharmacal Res 43(5):514–525 - DOI
    1. Akimoto H, Negishi A, Oshima S, Wakiyama H, Okita M, Horii N et al (2020) Antidiabetic drugs for the risk of alzheimer disease in patients with type 2 DM using FAERS. Am J Alzheimer’s Dis Other Dementias 35:1533317519899546
    1. Al-Majed A et al (2016) Pioglitazone. Profiles Drug Subst Excipients Relat Methodol 41:379–438 - DOI
    1. Arafa NMS, Ali EHA, Hassan MK (2017) Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action. Chem Biol Interact 277:195–203 - PubMed - DOI

Publication types

MeSH terms

LinkOut - more resources